ldb convergenze parallele_mantovani_02

17
Diego Mantovani, PhD, FBSE Lab. Biomaterials and Bioengineering Dept of Min-Met-Materials Eng. Research Center, CHU de Québec Université Laval

Upload: laboratoridalbasso

Post on 09-Jul-2015

63 views

Category:

Small Business & Entrepreneurship


0 download

TRANSCRIPT

Page 1: Ldb Convergenze Parallele_Mantovani_02

Diego Mantovani, PhD, FBSE

Lab. Biomaterials and Bioengineering

Dept of Min-Met-Materials Eng. Research Center, CHU de Québec

Université Laval

Page 2: Ldb Convergenze Parallele_Mantovani_02

www.lbb.ulaval.ca 2

Outline

Introduction The science behind the project – case study PI: what to do? Absolutely patenting (fiction) Absolutely licensing (fiction) The real case Side knowledge …

Page 3: Ldb Convergenze Parallele_Mantovani_02

The science behind the project

Grafting biomolecules to vascular prostheses by functionnalisation

Pascale Chevallier, Martin Castonguay, Jean-Francois Pageau, Diego Mantovani , Gaétan Laroche

Page 4: Ldb Convergenze Parallele_Mantovani_02

Vascular Prostheses

Page 5: Ldb Convergenze Parallele_Mantovani_02

Research Strategies Interfacial Problem

Blood Flow

Expected Obtained

Page 6: Ldb Convergenze Parallele_Mantovani_02

Plasma RF

Page 7: Ldb Convergenze Parallele_Mantovani_02

Rationale

Modification Surface Functionnalisation

Chemical Functionalities Bio-conjugation

AIM : anchoring specifically bioactive

molecules

Under vacuum

RFGD NH3

NH2

Page 8: Ldb Convergenze Parallele_Mantovani_02

RESULTS

1000 800 600 400 200 0 Binding energy (eV)

Virgin commercial prosthesis

Ammonia plasma

x 4

x 4

x 4

C 1s (32.8%)

F 1s (67.2%) F KLL F 2s

C 1s (55.4%) N 1s (12.2%)

F 1s (28.7%)

O 1s (3.7%) F 2s

F KLL

Ammonia plasma + bioactive molecules

F KLL

F 1s (12.7%) O 1s (16.2%) C 1s (57.7%)

N 1s (6.7%) F 2s

Cl 2p (2.11%)

Page 9: Ldb Convergenze Parallele_Mantovani_02

Results

Commercial prosthesis Treated prosthesis

Page 10: Ldb Convergenze Parallele_Mantovani_02

Platelets

* 5000 * 5000

Gore Tex Treated

Page 11: Ldb Convergenze Parallele_Mantovani_02

Cells

[cells] = 5*103 cells/ml during 7 days

Gore Tex Treated

* 20

* 20

Page 12: Ldb Convergenze Parallele_Mantovani_02

In vivo - dogs

/ *2000

Gore Tex Treated

Page 13: Ldb Convergenze Parallele_Mantovani_02

In vivo (6 mo. dogs)

Page 14: Ldb Convergenze Parallele_Mantovani_02

www.lbb.ulaval.ca 14

PI – what to do?

Patent? License? In site development under ultra conservative confidentiality?

Page 15: Ldb Convergenze Parallele_Mantovani_02

www.lbb.ulaval.ca 15

Absolutely patenting or absolutely licensing

Why? What? Where? How? Whom? For how long? What?

Page 16: Ldb Convergenze Parallele_Mantovani_02

www.lbb.ulaval.ca 16

(partial) Analyses and (some) criteria

Funding: governmental vs risk capital The environment, in term of:

• Risk analysis • Investors

Personal motivation

• Future and prospective consideration • Personal stimuli

Page 17: Ldb Convergenze Parallele_Mantovani_02

The real case …

2 patents on the technology 1 patent on a side technology (anti-fog!?) Spin-off (Materium) was created Licenses are under negotiation

University is happy, especially the TTO Scientists also but ... tired

D. Mantovani, 17 www.lbb.gmn.ulaval.ca